Diapositiva 1

Diapositiva 1

Non servono gli antiaritmici? Prof Luigi Padeletti Universit di Firenze Heart Failure & Co. Caserta, 29-30 aprile 2011 Sommario degli studi sul trattamento farmacologico Studio CAST-I1 Pazienti 1498 Disegno dello studio

Encainide, flecainide/ placebo Risultato Sospeso per numero eccessivo di decessi nel braccio di studio CHF-STAT2 674 Amiodarone/Placebo SWORD3 546

d-sotalolo/Placebo ESVEM4 486 EPS-guidato/Holterguidato EMIAT5 1500 Amiodarone/Placebo Nessuna variazione rispetto alla mortalit globale CAMIAT6

1200 Amiodarone/Placebo Nessuna variazione rispetto alla mortalit globale 1 Echt, et al. N Engl J Med. 1991;324:7818. 2 Singh, et al. N Engl J Med. 1995;333:7782 (supported by Sanofi & Wyeth). 3 Waldo A.L. The Lancet; 1996;348:712. (supported by Bristol-Myers Squibb). Nessuna variazione rispetto alla mortalit globale Sospeso per numero eccessivo di decessi nel braccio di studio Mortalit elevata in ambedue

i bracci 4 Mason J.W. N Engl J Med. 1993;329(7):4528. (Supported by BristolMyers Squibb, Knoll Pharmaceutical, Boehringer-Ingelheim, Parke-Davis, and Ciba-Geigy). 5 Julian D.G. The Lancet. 1997;349:66774.(Supported by Sanofi) 6 Cairns J.A. The Lancet. 1997;349:67582. Implanted Standby Defibrillators In fact, the implanted defibrillator system represents an imperfect solution in search of a plausible and practical application. Bernard Lown and Paul Axelrod Circulation, Volume XLVI, October 1972 Secondary Prevention Trials:

Reduction in Overall Mortality with ICD Therapy % Mortality Reduction w/ ICD Rx 80 60 40 31% 28% 20% 20 0 AVID

1 3 Years The AVID Investigators. N Engl J Med. 1997;337:1576-83. Kuck K. Circ.2000;102:748-54. 3 Connolly S. Circ. 2000;101:1297-1302. 1 2 CASH 2 3 Years CIDS 3

3 Years Secondary Prevention Trials: Reduction in Mortality with ICD Therapy % Mortality Reduction w/ ICD Rx 80 60 40 59% 56% 31%

Overall Death Arrhythmic Death 33% 28% 20% 20 0 AVID 1 3 Years The AVID Investigators. N Engl J Med. 1997;337:1576-83. Kuck K. Circ.2000;102:748-54. 3

Connolly S. Circ. 2000;101:1297-1302. 1 2 CASH 2 3 Years CIDS 3 3 Years Primary Prevention Post-MI Trials: Reduction in Overall Mortality with ICD Therapy % Mortality Reduction w/ ICD Rx 80

60 55% 54% 40 31% 20 0 MADIT 1 27 Months

Moss AJ. N Engl J Med. 1996;335:1933-40. Buxton AE. N Engl J Med. 1999;341:1882-90. 3 Moss AF. N Engl J Med. 2002;346:877-83. 1 2 MUSTT 2 39 Months MADIT-II 20 Months 3 Primary Prevention Post-MI Trials: Reduction in

Mortality with ICD Therapy % Mortality Reduction w/ ICD Rx 80 60 73% 75% Overall Death Arrhythmic Death 61% 55% 54%

40 31% 20 0 MADIT 1 27 Months MUSTT 2 39 Months

MADIT-II 3, 4 20 Months Moss AJ. N Engl J Med. 1996;335:1933-40. Buxton AE. N Engl J Med. 1999;341:1882-90. 3 Moss AF. N Engl J Med. 2002;346:877-83. 4 Moss AJ. Presented before ACC 51st Annual Scientific Sessions, Late Breaking Clinical Trials, March 19, 2002. 1 2 % Mortality Reduction w/ ICD Rx % Mortality Reduction w/ ICD Rx

Reductions in Overall Mortality with ICD Therapy 80 60 54% 55% 40 31% 20 ICD mortality reductions in primary prevention trials are equal to or greater than those in secondary

prevention trials. 0 MADIT 1 MUSTT 2 MADIT-II 27 months 39 months 20 months 3 80

60 40 31% 28% 20% 20 Moss AJ. N Engl J Med. 1996;335:1933-40. Buxton AE. N Engl J Med. 1999;341:1882-90. 3 Moss AJ. N Engl J Med. 2002;346:877-83 4 The AVID Investigators. N Engl J Med. 1997;337:1576-83. 5 Kuck K. Circ. 2000;102:748-54.

6 Connolly S. Circ. 2000:101:1297-1302. 1 0 2 AVID 4 3 Years CASH 5 3 Years CIDS 6 3 Years % Mortality Reduction w/ ICD Rx

% Mortality Reduction w/ ICD Rx Reductions in Mortality with ICD Therapy 80 60 75% 76% Overall Death Arrhythmic Death 61% 55% 54%

40 31% 20 ICD mortality reductions in primary prevention trials are equal to or greater than those in secondary prevention trials. 0 MADIT 1 MUSTT 2 MADIT-II

3, 4 27 months 39 months 20 months 80 60 40 59% 56% 31%

Overall Death Arrhythmic Death 33% 28% 20% 20 Moss AJ. N Engl J Med. 1996;335:1933-40. Buxton AE. N Engl J Med. 1999;341:1882-90. 3 Moss AJ. N Engl J Med. 2002;346:877-83 4 Moss AJ. Presented before ACC 51st Annual Scientific Sessions, Late Breaking Clinical Trials, March 19, 2002. 5

The AVID Investigators. N Engl J Med. 1997;337:1576-83. 6 Kuck K. Circ. 2000;102:748-54. 7 Connolly S. Circ. 2000:101:1297-1302. 1 2 0 AVID 5 3 Years CASH 6 3 Years CIDS 7 3 Years Reason for treatment with AADs in ICD recipients

Prognostic importance of defibrillator shocks in patients with heart failure Benefits of adjuvant AADs in ICD patients Betabloccanti: Effetti sulla mortalit 26 trials > 24.000 pts Post-infarto BETABLOCCANTI PLACEBO RIDUZIONE

Mortalit Totale 934/12438 (7.5%) 1124/11860 (9.5%) - 21% Morte Improvvisa 288/8115 (3.5%) 401/7706 (5.2%) - 33%

YUSUF S. et al. Prog Cardiovas Dis, 1985; 17: 335-371 Clinical Trial summarizing Benefits of AADs Clinical Trial summarizing Benefits of AADs OPTIC Trial Side Effects of Beta-Blockers could be Beneficial Conclusions Adjunctive AAD therapy often is necessary in many patients with ICDs for control of recurrent ventricular tachyarrhythmias and prevention of ICD

shocks. Conclusions Given the scarsity of safe and effective AADs for this indication, the decision of when to start an AAD in the patient with an ICD must be individualized. Conclusions If AAD therapy is initiated, the potential for drug-related toxicities and device interactions must be recognized and anticipated.

Recently Viewed Presentations

  • A.p. Statistics Lesson 6.3 (Day 1)

    A.p. Statistics Lesson 6.3 (Day 1)

    AP STATISTICS LESSON 6.3 (DAY 1) ... Addition rule: If A and B are disjoint events, then P(A or B ) = P(A) + P(B) Rule 5: Multiplication rule: If A and B are independent events, then P(A and B)...
  • ThermodynamicsChange in Enthalpy, H

    ThermodynamicsChange in Enthalpy, H

    Enthalpy change for a reaction is equal in magnitude but opposite in sign to the H for the reverse reaction. 3 CO. 2 (g) + 4 H 2 O (g) C 3 H 8 (g) + 5 O 2 (g)...
  • Industry Perspective on Energy Storage Issues

    Industry Perspective on Energy Storage Issues

    Industry Perspective on Energy Storage Issues. TVNRG is a Texas based Solar Energy and Energy Storage Developer and the Texas Affiliate of Borrego Solar. Presentation gives an industry perspective on Energy Storage benefits and inhibitors to development. Cyrus Reed dovetails...
  • Presentazione di PowerPoint - Alcatel Mobile

    Presentazione di PowerPoint - Alcatel Mobile

    Sometimes in Your ALCATEL ONETOUCH Smartphone with Android will need to return to factory settings, or maybe just have a backup of the information stored on it, but do not worry, among the new applications on your smartphone and thinking...
  • The Hungry Little Hare

    The Hungry Little Hare

    The Hungry Little Hare Unit 3 Lesson 3 By Mrs. Nailon disguise Something that changes or hides the way one looks. costume scent A smell. disappear Not able to be seen.
  • Impacts of the economic crisis: experience from rapid,

    Impacts of the economic crisis: experience from rapid,

    Adapting business strategies. Expansion of income generating activities. Constrain consumption of luxuries. Extending working hours. Evidence of Vulnerability. Cutting back basic consumption. ... Non-crisis shocks -seasonal price change, school fees.
  • Seattle Office for civil rights office of labor standards ...

    Seattle Office for civil rights office of labor standards ...

    nterest. Subsequent Violations. Mandatory 3x unpaid wages + interest. First Violation. U p to $500 per aggrieved party. Second Violation. Up to $1000 per aggrieved party or 10% of unpaid wages, whichever is greater. Third Violation. Up to $5,000 per...
  • What is a Fish?

    What is a Fish?

    Reproduction & Spawning Reproductive strategies Sex determination Spawning behaviors Reproductive strategies No general evolutionary trend from primitive to advanced groups All strategies are valid and evolutionary adaptive Reproductive strategies-1 Nonguarders (of eggs and young) Open Substrate Spawners Pelagic Scatterers (pelagic...